Literature DB >> 364060

Synthesis and biological activity of highly active alpha-aza analogues of luliberin.

A S Dutta, B J Furr, M B Giles, B Valcaccia.   

Abstract

Analogues of luliberin containing an alpha-azaamino acid in position 6, 9, or 10 (I--XIV) have been synthesized by the solution method of peptide synthesis. Two nonaza analogues, [D-Phe6]- and [D-Ser(But)6,des-Gly-NH2(10),Pro-ethylamide9]luliberin, were also synthesized for comparison. The ovulation-inducing activity of the compounds was evaluated in androgen-sterilized constant-estrus rats. A combination of D-amino acid replacement in position 6 with an azaglycine residue at position 10 resulted in highly active compounds which were superior to the corresponding nonaza analogues. The most active compoungs, [D-Phe6,Azgly10-a1-, [D-Tyr(Me)6,Azgly10]-, and [D-Ser(But)6,Azgly10]luliberin, were about 100 times as potent as luliberin. N-Methylleucine substitution in position 7 in these compounds resulted in decreased activity; [D-Phe6,MeLeu7,Azgly10]- and [D-Tyr(Me)6,MeLeu7,Azgly10]luliberin were only 50 times as active as luliberin. The presence of either an azaproline residue in position 9, an azaphenylalanine or azaglycine residue in positions 6 and 10, or a tert-butyl ether protecting group on the hydroxyl group of the tyrosine residue in position 5 resulted in compounds with significantly reduced biological activity.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 364060     DOI: 10.1021/jm00208a004

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  7 in total

Review 1.  Luteinizing hormone-releasing hormone and its analogues: a review of biological properties and clinical uses.

Authors:  B J Furr; J R Woodburn
Journal:  J Endocrinol Invest       Date:  1988 Jul-Aug       Impact factor: 4.256

Review 2.  Goserelin. A review of its pharmacodynamic and pharmacokinetic properties, and clinical use in sex hormone-related conditions.

Authors:  P Chrisp; K L Goa
Journal:  Drugs       Date:  1991-02       Impact factor: 9.546

3.  Unresponsiveness of the reproductive organs of the male mouse to treatment with a potent luteinizing hormone-releasing hormone agonist (ICI-118,630).

Authors:  G J van Steenbrugge; J C Romijn; F H de Jong; F H Schröder
Journal:  Urol Res       Date:  1984

4.  A Single Stereodynamic Center Modulates the Rate of Self-Assembly in a Biomolecular System.

Authors:  Yitao Zhang; Roy M Malamakal; David M Chenoweth
Journal:  Angew Chem Int Ed Engl       Date:  2015-07-23       Impact factor: 15.336

Review 5.  Urea-based anticancer agents. Exploring 100-years of research with an eye to the future.

Authors:  Roberta Listro; Giacomo Rossino; Federica Piaggi; Falilat Folasade Sonekan; Daniela Rossi; Pasquale Linciano; Simona Collina
Journal:  Front Chem       Date:  2022-09-15       Impact factor: 5.545

6.  Effects of high doses of a series of new luteinizing hormone-releasing hormone analogues in intact female rats.

Authors:  P V Maynard; R I Nicholson
Journal:  Br J Cancer       Date:  1979-03       Impact factor: 7.640

7.  Anti-tumour activity of ICI 118630, a new potent luteinizing hormone-releasing hormone agonist.

Authors:  R I Nicholson; P V Maynard
Journal:  Br J Cancer       Date:  1979-03       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.